Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Gabe Ortiz, MD, PhD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1001 Potrero Ave
    San Francisco CA 94110
    Phone415-206-2355
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Yale UniveristyMS, BSMolecular Biophysics and Biochemistry1996
      Tri-Institutional MD, PhD Program of Weill Cornell, the Rockefeller, and Memorial Sloan-KetteringMD, PhDMedicine and Human Immunology2004
      UCSFResidencyInternal Medicine2007
      UCSFChief ResidencyInternal Medicine2008
      UCSFFellowshipInfectious Diseases2012

      Collapse Overview 
      Collapse Overview
      Gabriel Ortiz (aka, Gabe) joined the Division of Hospital Medicine at Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) in 2012 in order to apply his clinical and analytic skills to quality improvement work to better the care delivered to the vulnerable communities served by this county hospital. Gabe's primary area of quality improvement work is centered around hospital operations and improving patient flow, which lies at the nexus of patient safety, patient satisfaction, and clinical quality. Gabe is certified in Toyota's LEAN production and LEAN daily management systems, and he is an avid "PDSA-er". He has contributed to the kaizen work of multiple value streams across the ZSFG campus (see featured videos for report-out links located on this profile page, below) including Med/Surg, Emergency Department, Pharmacy, Radiology, and Urgent Care, and he has contributed significantly to the 3P Design Process to lay the foundation for the patient-centered, flexible acuity model that is currently practiced in the new hospital tower of Zuckerberg San Francisco General that was opened in May 2016. Further, Gabe is a member of the ED Leadership Team, the Med/Surg Steering Committee, CPG Committee, and various other important committees at ZSFG. As part of his operational interests and in addition to the application of QI principles to hospital operations, Gabe is the clinical lead for designing and implementing electronic workflows used for delivering clinical care in the inpatient setting in preparation for an enterprise EHR implementation in the future.

      Gabe continues to be devoted to improving patient flow and hospital operations with the aim to ensure the highest quality care is delivered to our most vulnerable.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Haber LA, Ortiz GM. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. J Hosp Med. 2014 Dec; 9(12):805-7. PMID: 25352497.
        View in: PubMed
      2. Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014; 11:27. PMID: 25180041; PMCID: PMC4150425.
      3. Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS One. 2013; 8(12):e84091. PMID: 24391889; PMCID: PMC3877182.
      4. Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics. 2012 Sep; 11(9):605-18. PMID: 22580588; PMCID: PMC3434775.
      5. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses. 2006 Jan; 22(1):52-6. PMID: 16438646.
        View in: PubMed
      6. Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr. 2004 Jul 1; 36(3):791-9. PMID: 15213562.
        View in: PubMed
      7. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):475-81. PMID: 14657757.
        View in: PubMed
      8. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. PMID: 12767994; PMCID: PMC156163.
      9. García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. 2003 Jan 3; 17(1):43-51. PMID: 12478068.
        View in: PubMed
      10. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. PMID: 12441810.
        View in: PubMed
      11. Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol. 2002 Jan; 76(1):411-5. PMID: 11739706; PMCID: PMC135693.
      12. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13288-93. PMID: 11687611; PMCID: PMC60863.
      13. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001 Jun 15; 15(9):F29-40. PMID: 11416735.
        View in: PubMed
      14. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS. 2000 Oct 20; 14(15):2313-22. PMID: 11089619.
        View in: PubMed
      15. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep; 182(3):766-75. PMID: 10950770.
        View in: PubMed
      16. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000 Apr; 181(4):1249-63. PMID: 10762561.
        View in: PubMed
      17. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999 Sep; 104(6):R13-8. PMID: 10491418; PMCID: PMC408442.
      18. Gabriel M. Ortiz and David Graham. . “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org.
      Gabe's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP